AB Corporate Bond ETF (NASDAQ:EYEG) Stock Price Crosses Below 200 Day Moving Average – Time to Sell?

Shares of AB Corporate Bond ETF (NASDAQ:EYEG) passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $35.48 and traded as low as $34.76. AB Corporate Bond ETF shares last traded at $34.7690, with a volume of 18 shares.

AB Corporate Bond ETF Stock Performance

The business has a fifty day simple moving average of $35.16 and a 200-day simple moving average of $35.48. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.01. The firm has a market cap of $27.82 million, a P/E ratio of -20.70 and a beta of 0.17.

AB Corporate Bond ETF Cuts Dividend

The firm also recently announced a monthly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Wednesday, July 1st were given a $0.1358 dividend. The ex-dividend date of this dividend was Wednesday, July 1st. This represents a c) dividend on an annualized basis and a dividend yield of 4.7%. AB Corporate Bond ETF’s dividend payout ratio is currently -102.98%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of EYEG. Kestra Advisory Services LLC purchased a new position in AB Corporate Bond ETF during the 4th quarter valued at about $34,000. Jane Street Group LLC bought a new stake in AB Corporate Bond ETF during the second quarter worth about $232,000. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in AB Corporate Bond ETF by 32.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock worth $5,634,000 after purchasing an additional 38,685 shares during the period. 64.16% of the stock is currently owned by institutional investors.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.